{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:19:55Z","timestamp":1791508795002,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00192-024-05809-0","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T09:01:46Z","timestamp":1716022906000},"page":"1317-1322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-761X","authenticated-orcid":false,"given":"Anastasia","family":"Beta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilia","family":"Mantzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios","family":"Deligeoroglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Bakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"1","key":"5809_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37\u201349.","journal-title":"Urology"},{"issue":"6","key":"5809_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"1","key":"5809_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5\u201326.","journal-title":"Int Urogynecol J"},{"issue":"5","key":"5809_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/nau.22609","volume":"33","author":"MJ Drake","year":"2014","unstructured":"Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622\u20134.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5809_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/nau.1930070605","volume":"7","author":"E McGuire","year":"1988","unstructured":"McGuire E. Bladder instability and stress incontinence. Neurourol Urodyn. 1988;7(6):563\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"5809_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1464-410X.1980.tb03058.x","volume":"52","author":"CP Bates","year":"1980","unstructured":"Bates CP, Bradley WE, Glen ES, et al. Third Report on the Standardisation of Terminology of Lower Urinary Tract Function: procedures related to the evaluation of micturition: pressure-flow relationships. Residual urine. Br J Urol. 1980;52(5):348\u201350.","journal-title":"Br J Urol"},{"issue":"5","key":"5809_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/14740338.2016.1165663","volume":"15","author":"D Robinson","year":"2016","unstructured":"Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf. 2016;15(5):689\u201396.","journal-title":"Expert Opin Drug Saf"},{"key":"5809_CR8","unstructured":"Mirabegron. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 2 September 2023. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547887\/"},{"issue":"2","key":"5809_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1254\/jphs.09R12FM","volume":"112","author":"M Yoshida","year":"2010","unstructured":"Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci. 2010;112(2):128\u201334.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"5809_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/nau.22438","volume":"33","author":"CD Cruz","year":"2014","unstructured":"Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39\u201345.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"5809_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nrurol.2012.178","volume":"9","author":"P Ochodnicky","year":"2012","unstructured":"Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012;9(11):628\u201337.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"5809_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/nau.21022","volume":"30","author":"P Ochodnick\u00fd","year":"2011","unstructured":"Ochodnick\u00fd P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227\u201341.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"5809_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/01.ju.0000165461.38088.7b","volume":"174","author":"A Nixon","year":"2005","unstructured":"Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;174(2):604\u20137. https:\/\/doi.org\/10.1097\/01.ju.0000165461.38088.7b.","journal-title":"J Urol"},{"issue":"Suppl 4","key":"5809_CR14","first-page":"S7","volume":"4","author":"WD Steers","year":"2002","unstructured":"Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7\u201318.","journal-title":"Rev Urol"},{"issue":"11","key":"5809_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2174\/1570159X17666190617095844","volume":"17","author":"A Coelho","year":"2019","unstructured":"Coelho A, Oliveira R, Antunes-Lopes T, Duarte Cruz C. Partners in crime: NGF and BDNF in visceral dysfunction. Curr Neuropharmacol. 2019;17(11):1021\u201338. https:\/\/doi.org\/10.2174\/1570159X17666190617095844.","journal-title":"Curr Neuropharmacol"},{"key":"5809_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12894-015-0036-3","volume":"15","author":"SM Yuk","year":"2015","unstructured":"Yuk SM, Shin JH, Song KH, Na YG, Lim JS, Sul CK. Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function. BMC Urol. 2015;15:37. https:\/\/doi.org\/10.1186\/s12894-015-0036-3","journal-title":"BMC Urol"},{"issue":"6","key":"5809_CR17","first-page":"559","volume":"11","author":"C Cheng","year":"2023","unstructured":"Cheng C, Li Q, Lin G, Opara EC, Zhang Y. Neurobiological insights into lower urinary tract dysfunction: evaluating the role of brain-derived neurotrophic factor. Am J Clin Exp Urol. 2023;11(6):559\u201377","journal-title":"Am J Clin Exp Urol"},{"issue":"1","key":"5809_CR18","doi-asserted-by":"publisher","first-page":"F45","DOI":"10.1152\/ajprenal.00386.2017","volume":"315","author":"MP Kashyap","year":"2018","unstructured":"Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Renal Physiol. 2018;315(1):F45\u201356.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"5809_CR19","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00192-021-04945-1","volume":"32","author":"S Tsiapakidou","year":"2021","unstructured":"Tsiapakidou S, Apostolidis A, Pantazis K, Grimbizis GF, Mikos T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int Urogynecol J. 2021;32(12):3143\u201355.","journal-title":"Int Urogynecol J"},{"issue":"5","key":"5809_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1464-410X.2010.09585.x","volume":"107","author":"HT Liu","year":"2011","unstructured":"Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011;107(5):799\u2013803.","journal-title":"BJU Int"},{"issue":"1","key":"5809_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.juro.2012.08.187","volume":"189","author":"T Antunes-Lopes","year":"2013","unstructured":"Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1)):359\u201365. https:\/\/doi.org\/10.1016\/j.juro.2012.08.187","journal-title":"J Urol"},{"issue":"4","key":"5809_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5213\/inj.1732794.397","volume":"21","author":"YS Suh","year":"2017","unstructured":"Suh YS, Ko KJ, Kim TH, et al. Urinary nerve growth factor as a potential biomarker of treatment outcomes in overactive bladder patients. Int Neurourol J. 2017;21(4):270\u201381.","journal-title":"Int Neurourol J"},{"issue":"3","key":"5809_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5152\/tud.2020.20432","volume":"47","author":"S Sa\u011f\u0131r","year":"2021","unstructured":"Sa\u011f\u0131r S, Bayrak \u00d6, \u015een H, Kul S, Erturhan S, Se\u00e7kiner \u0130. Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection. Turk J Urol. 2021;47(3):223\u20138.","journal-title":"Turk J Urol"},{"issue":"1","key":"5809_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1748-1716.2012.02462.x","volume":"207","author":"LA Birder","year":"2013","unstructured":"Birder LA, Wolf-Johnston AS, Sun Y, Chai TC. Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf). 2013;207(1):123\u20139.","journal-title":"Acta Physiol (Oxf)"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-05809-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-024-05809-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-05809-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:04:09Z","timestamp":1720778649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-024-05809-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5809"],"URL":"https:\/\/doi.org\/10.1007\/s00192-024-05809-0","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"18 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}